DGAP-News: Defence Therapeutics Inc.: DEFENCE RELEASES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUVAC-D001L IN CELL REPORTS MEDICINE JOURNAL
DGAP-News: Defence Therapeutics Inc.
/ Key word(s): Miscellaneous
CSE: DTC FSE: DTC USOTC: DTCFF DEFENCE RELEASES PEER-REVIEWED PUBLICATION OF ITS PRECLINICAL DATA ON ACCUVAC-D001L IN CELL REPORTS MEDICINE JOURNAL Vancouver, BC, Canada, February 28th, 2022 - Defence Therapeutics Inc. ("Defence" or the "Company"), a pre-clinical biotechnology company developing various products for the immune-oncology space, is pleased to announce the publication of its first peer-reviewed study on the potency of AccuVAC-D001L. AccuVAC-D001L is one of Defence's dendritic cell (DC) vaccine products designed to treat established T-cell lymphoma developed from Defence's patented AccumTM technologies. This study, which was published in the prestigious journal of Cell Reports Medicine, is entitled, "Promoting antigen escape from dendritic cell endosomes potentiates anti-tumoral immunity", and can be directly accessed at the following address: https://doi.org/10.1016/j.xcrm.2022.100534" There is currently only one FDA-approved DC vaccine available on the market and it is dedicated to the treatment of prostate cancer. However, the vaccine did not deliver the hoped-for clinical outcome due to major hurdles related to antigen presentation by DCs to responding T cells. This is where AccumTM technology shows itself as a major advantage, as it provides the cues needed to bypass the number one enemy of any given antigen: endosomal entrapment. The study, which was led by the VP of research and development at Defence, Dr. Rafei, presents insights of how Accum-linked antigens escape DC endosomes, which results in their efficient processing by the proteasomal complex. T cells are thus effectively activated culminating in potent control of established tumors or even their complete regression in certain cases. A more detailed analysis of treated tumors further revealed re-activation of the host immune system within the tumor microenvironment resulting in the recruitment of potent effector cells such as CD8 lymphocytes, NK cells, as well as endogenous DCs. The latter population is particularly important as it may further amplify the triggered anti-tumoral response by participating in capturing and presenting additional tumor-derived antigens. Compared to the existing standard DC vaccine, Defence's intratumoral delivery of AccuVAC-D001L affected the tumor microenvironment tipping the balance in favor of cytotoxic T lymphocytes at the expense of the suppressive regulatory T cells. These preclinical findings represent a giant step in the field of DC vaccination and may provide the impetus to recycle past DC vaccines with failed clinical efficacy. The key highlights of the AccuVAC-D001L study are:
"This prestigious peer-reviewed publication provides important validation of our first DC vaccine candidate, and demonstrates the advantages of using our AccumTM antigen formulation to enhance the anti-tumoral response of DC-based vaccination," said Mr. Plouffe, Chief Executive Officer of Defence Therapeutics. In summary, AccuVAC-D001L is developed by Defence's scientific team and engineered to overcome most of DC vaccine shortcomings using Defence's AccumTM Technology platform. The triggered durable and potent memory response combined with the observed favorable safety profile positions this DC vaccination platform as a base for future cancer vaccination strategies. The use of Accum-antigen formulations provides a versatile framework for a wide range of other DC vaccines to target multiple cancer indications. The human AccuVAC-D001L is currently being generated in a clean room installation in preparation for the melanoma Phase I trial expected to start in Q4 of 2022. For further information:
28.02.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. |
Language: | English |
Company: | Defence Therapeutics Inc. |
1680 - 200 Burrard St | |
V6C3L6 Vancouver | |
Canada | |
E-mail: | [email protected] |
Internet: | https://defencetherapeutics.com |
ISIN: | CA24463V1013 |
WKN: | A3CN14 |
Listed: | Regulated Unofficial Market in Frankfurt, Stuttgart; Toronto |
EQS News ID: | 1289343 |
End of News | DGAP News Service |
|
1289343 28.02.2022